Project Grant R01HL176803
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$637K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award, with ID R01HL177013, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $684,814 award supports research to investigate how lung tissue factors can alter the inflammatory response to viral infections and suppress alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). Key objectives include determining the mechanisms by which stromal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $672,657 to support research on the role of transmembrane protein 178 (TMEM178) in asthma pathogenesis. The key objectives are to: 1) Investigate how TMEM178-mediated inhibition of calcium responses is disrupted in asthmatic bronchial epithelial cells; 2) Analyze the impact of targeted genetic loss of TMEM178 in the epithelium...
The federal Project Grant award R01HL177625, worth $616,814.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective January 15, 2025, supports research to establish the in vivo role of key microRNAs in regulating airway smooth muscle function and airway hyperresponsiveness, and to demonstrate how the dysregulation of these microRNAs contributes to human asthma and impacts response to asthma...
This federal Project Grant award, valued at $387,116 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the neural mechanisms triggered by house dust mite (HDM) exposure that lead to the development of airway hyperreactivity in asthma. The study aims to identify the specific nerve subtypes and signaling pathways activated by HDM components, and determine how this chronic activation...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $777,497 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. This 4-year grant, commencing on September 15, 2024, will support research to investigate how the circadian clock mediates the adult age, pro-resolution response to viral asthma triggers. The proposed research will use mouse models and patient samples to examine how the circadian clock within...
The University of Washington was awarded a $880,735 Project Grant (R01HL172817) under the Cardiovascular Diseases Research program (CFDA 93.837) by the National Heart, Lung, and Blood Institute (NHLBI). The project aims to investigate the mechanisms by which cell lysis-induced leukotriene synthesis activates type-2 immunity in the lung. Key research objectives include identifying alveolar macrophages as a source of leukotriene C4, examining the contributions of leukotrienes to innate type-2...
This $775,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and the impact of host genetic variability. The key objectives are to: Determine the function of Treg glucocorticoid receptor (GR) signaling and the effects of exogenous...
The National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). This grant, effective July 1, 2024 through November 30, 2026, will support UCSF's research to adapt cell-based therapies for the treatment of pulmonary fibrosis. As a leading academic medical research institution, UCSF...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189.00 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The primary objectives are to study epithelial regulation of fibrosis and innate immunity against bacterial infections in the lungs, as well as test delivery of targeted therapies using nanoparticles. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Biotherapeutics, Inc. a $355,935 Project Grant under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) to develop a novel, oral immunoregulatory therapeutic for the treatment of asthma. The goal is to create an innovative treatment that targets a new immunoregulatory pathway in immune and epithelial cells to address the significant unmet medical need for safer and more effective asthma therapies, particularly...